1. Home
  2. NOTV vs NTHI Comparison

NOTV vs NTHI Comparison

Compare NOTV & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inotiv Inc.

NOTV

Inotiv Inc.

HOLD

Current Price

$0.76

Market Cap

29.9M

Sector

Health Care

ML Signal

HOLD

NTHI

NeOnc Technologies Holdings Inc.

N/A

Current Price

$10.19

Market Cap

195.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOTV
NTHI
Founded
1974
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.9M
195.5M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
NOTV
NTHI
Price
$0.76
$10.19
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
1.6M
68.0K
Earning Date
12-03-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$513,024,000.00
$59,990.00
Revenue This Year
$6.26
N/A
Revenue Next Year
$45.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.54
N/A
52 Week Low
$0.66
$3.20
52 Week High
$6.48
$25.00

Technical Indicators

Market Signals
Indicator
NOTV
NTHI
Relative Strength Index (RSI) 35.16 58.54
Support Level $0.79 $8.63
Resistance Level $0.86 $9.75
Average True Range (ATR) 0.07 0.88
MACD 0.01 0.23
Stochastic Oscillator 3.93 95.59

Price Performance

Historical Comparison
NOTV
NTHI

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).

Share on Social Networks: